Does the media refer more to MLTX or DNTH?

In the previous week, MoonLake Immunotherapeutics had 8 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 7 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.03 beat MoonLake Immunotherapeutics' score of 0.74 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ORKA or MLTX?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oruka Therapeutics N/A N/A -$105.43M -$1.94 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is ORKA or MLTX more profitable?

Oruka Therapeutics' return on equity of -26.16% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -26.16% -25.00% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media refer more to ORKA or MLTX?

In the previous week, MoonLake Immunotherapeutics had 10 more articles in the media than Oruka Therapeutics. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat MoonLake Immunotherapeutics' score of 0.74 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GRFS or MLTX?

In the previous week, MoonLake Immunotherapeutics had 13 more articles in the media than Grifols. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 2 mentions for Grifols. Grifols' average media sentiment score of 0.93 beat MoonLake Immunotherapeutics' score of 0.74 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLTX or TVTX?

In the previous week, MoonLake Immunotherapeutics had 10 more articles in the media than Travere Therapeutics. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 5 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.75 beat MoonLake Immunotherapeutics' score of 0.74 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

MoonLake Immunotherapeutics (MLTX) Competitors

$19.02 -0.34 (-1.76%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$19.16 +0.14 (+0.74%)

As of 07/24/2026 07:34 PM Eastern

Compare

MLTX vs. DNTH, ORKA, GRFS, TVTX, and KNSA

Should you buy MoonLake Immunotherapeutics stock or one of its competitors? MarketBeat compares MoonLake Immunotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MoonLake Immunotherapeutics include Dianthus Therapeutics (DNTH), Oruka Therapeutics (ORKA), Grifols (GRFS), Travere Therapeutics (TVTX), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does MoonLake Immunotherapeutics compare to Dianthus Therapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics presently has a consensus target price of $24.21, suggesting a potential upside of 27.31%. Dianthus Therapeutics has a consensus target price of $117.82, suggesting a potential upside of 13.43%. Given MoonLake Immunotherapeutics' higher possible upside, equities research analysts plainly believe MoonLake Immunotherapeutics is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, MoonLake Immunotherapeutics had 8 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 7 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.03 beat MoonLake Immunotherapeutics' score of 0.74 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Dianthus Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Dianthus Therapeutics	$2.04M	2,783.61	-$162.34M	-$4.13	N/A

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Summary

Dianthus Therapeutics beats MoonLake Immunotherapeutics on 9 of the 16 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Oruka Therapeutics currently has a consensus price target of $134.30, suggesting a potential upside of 45.72%. MoonLake Immunotherapeutics has a consensus price target of $24.21, suggesting a potential upside of 27.31%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Oruka Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Oruka Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Oruka Therapeutics' return on equity of -26.16% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Oruka Therapeutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, MoonLake Immunotherapeutics had 10 more articles in the media than Oruka Therapeutics. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat MoonLake Immunotherapeutics' score of 0.74 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oruka Therapeutics beats MoonLake Immunotherapeutics on 8 of the 12 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Grifols?

Grifols (NASDAQ:GRFS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Grifols has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.61	$454.82M	$0.19	39.89
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Grifols has a net margin of 5.54% compared to MoonLake Immunotherapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Grifols has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Grifols currently has a consensus target price of $10.00, suggesting a potential upside of 31.93%. MoonLake Immunotherapeutics has a consensus target price of $24.21, suggesting a potential upside of 27.31%. Given Grifols' higher probable upside, analysts plainly believe Grifols is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

In the previous week, MoonLake Immunotherapeutics had 13 more articles in the media than Grifols. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 2 mentions for Grifols. Grifols' average media sentiment score of 0.93 beat MoonLake Immunotherapeutics' score of 0.74 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Grifols beats MoonLake Immunotherapeutics on 9 of the 15 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Travere Therapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Travere Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Travere Therapeutics	$536.20M	9.95	-$25.55M	-$0.23	N/A

In the previous week, MoonLake Immunotherapeutics had 10 more articles in the media than Travere Therapeutics. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 5 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.75 beat MoonLake Immunotherapeutics' score of 0.74 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

MoonLake Immunotherapeutics presently has a consensus price target of $24.21, indicating a potential upside of 27.31%. Travere Therapeutics has a consensus price target of $52.08, indicating a potential downside of 9.20%. Given MoonLake Immunotherapeutics' higher probable upside, research analysts plainly believe MoonLake Immunotherapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -4.00%. Travere Therapeutics' return on equity of -26.16% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Summary

Travere Therapeutics beats MoonLake Immunotherapeutics on 8 of the 14 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Kiniksa Pharmaceuticals International?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to MoonLake Immunotherapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kiniksa Pharmaceuticals International has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Kiniksa Pharmaceuticals International	$754.05M	6.41	$59.01M	$0.90	69.82

In the previous week, MoonLake Immunotherapeutics had 7 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 8 mentions for Kiniksa Pharmaceuticals International. MoonLake Immunotherapeutics' average media sentiment score of 0.74 beat Kiniksa Pharmaceuticals International's score of 0.49 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MoonLake Immunotherapeutics presently has a consensus target price of $24.21, indicating a potential upside of 27.31%. Kiniksa Pharmaceuticals International has a consensus target price of $68.00, indicating a potential upside of 8.21%. Given MoonLake Immunotherapeutics' higher probable upside, research analysts clearly believe MoonLake Immunotherapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market.

Summary

Kiniksa Pharmaceuticals International beats MoonLake Immunotherapeutics on 10 of the 16 factors compared between the two stocks.

Get MoonLake Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLTX vs. The Competition

Export

Metric	MoonLake Immunotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.43B	$3.67B	$6.88B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-4.91	21.11	27.00	23.71
Price / Sales	N/A	166.46	491.80	74.83
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	4.45	7.88	10.28	6.07
Net Income	-$227.32M	$23.81M	$3.60B	$331.84M
7 Day Performance	-3.35%	-3.79%	-1.25%	-1.53%
1 Month Performance	-4.85%	-2.59%	-0.35%	-2.46%
1 Year Performance	-65.46%	32.85%	18.41%	13.66%

MoonLake Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLTX MoonLake Immunotherapeutics	3.2022 of 5 stars	$19.02 -1.8%	$24.21 +27.3%	-65.4%	$1.43B	N/A	N/A	2	Analyst Revision
DNTH Dianthus Therapeutics	2.2889 of 5 stars	$104.08 +3.0%	$117.82 +13.2%	+376.7%	$5.68B	$2.04M	N/A	80	News Coverage Positive News
ORKA Oruka Therapeutics	3.6307 of 5 stars	$93.88 +2.4%	$134.30 +43.1%	+547.6%	$5.66B	N/A	N/A	N/A	News Coverage Positive News
GRFS Grifols	4.4969 of 5 stars	$7.72 +1.4%	$10.00 +29.6%	-23.7%	$5.25B	$8.51B	40.61	25,247	Upcoming Earnings
TVTX Travere Therapeutics	1.9206 of 5 stars	$56.21 +1.3%	$52.08 -7.3%	+259.6%	$5.22B	$490.73M	N/A	460	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLTX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. DNTH, ORKA, GRFS, TVTX, and KNSA

How does MoonLake Immunotherapeutics compare to Dianthus Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Oruka Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Grifols?

Summary

How does MoonLake Immunotherapeutics compare to Travere Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. DNTH, ORKA, GRFS, TVTX, and KNSA

How does MoonLake Immunotherapeutics compare to Dianthus Therapeutics?

Do institutionals & insiders hold more shares of MLTX or DNTH?

Do analysts prefer MLTX or DNTH?

Does the media refer more to MLTX or DNTH?

Which has more volatility and risk, MLTX or DNTH?

Which has better valuation and earnings, MLTX or DNTH?

Is MLTX or DNTH more profitable?

Summary

How does MoonLake Immunotherapeutics compare to Oruka Therapeutics?

Do analysts rate ORKA or MLTX?

Which has higher earnings & valuation, ORKA or MLTX?

Is ORKA or MLTX more profitable?

Which has more risk & volatility, ORKA or MLTX?

Do insiders & institutionals hold more shares of ORKA or MLTX?

Does the media refer more to ORKA or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Grifols?

Which has preferable valuation & earnings, GRFS or MLTX?

Do insiders and institutionals hold more shares of GRFS or MLTX?

Is GRFS or MLTX more profitable?

Which has more risk and volatility, GRFS or MLTX?

Do analysts rate GRFS or MLTX?

Does the media prefer GRFS or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Travere Therapeutics?

Which has preferable valuation & earnings, MLTX or TVTX?

Does the media refer more to MLTX or TVTX?

Do analysts recommend MLTX or TVTX?

Is MLTX or TVTX more profitable?

Do institutionals & insiders believe in MLTX or TVTX?

Which has more volatility & risk, MLTX or TVTX?

Summary

How does MoonLake Immunotherapeutics compare to Kiniksa Pharmaceuticals International?

Is MLTX or KNSA more profitable?

Do insiders & institutionals believe in MLTX or KNSA?

Which has preferable earnings & valuation, MLTX or KNSA?

Does the media favor MLTX or KNSA?

Do analysts rate MLTX or KNSA?

Which has more risk & volatility, MLTX or KNSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools